100 项与 COVID-19 vaccine (Mass General Brigham) 相关的临床结果
100 项与 COVID-19 vaccine (Mass General Brigham) 相关的专利（医药）
项与 COVID-19 vaccine (Mass General Brigham) 相关的文献（医药）
2022-04-15·Viruses3区 · 医学
Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging.
3区 · 医学
作者: Dawid Maciorowski ; Cheikh Diop ; Urja Bhatt ; Reynette Estelien ; Dan Li ; Ruchi Chauhan ; Luk H Vandenberghe ; Nerea Zabaleta
The SARS-CoV-2 pandemic has had a disastrous impact on global health. Although some vaccine candidates have been effective in combating SARS-CoV-2, logistical, economical, and sociological aspects still limit vaccine access globally. Recently, we reported on two room-temperature stable AAV-based COVID-19 vaccines that induced potent and protective immunogenicity following a single injection in murine and primate models. Obesity and old age are associated with increased mortality in COVID-19, as well as reduced immunogenicity and efficacy of vaccines. Here, we investigated the effectiveness of the AAVCOVID vaccine candidates in murine models of obesity and aging. Results demonstrate that obesity did not significantly alter the immunogenicity of either vaccine candidate. In aged mice, vaccine immunogenicity was impaired. These results suggest that AAV-based vaccines may have limitations in older populations and may be equally applicable in obese and non-obese populations.
2021-08-07·Cell host & microbe1区 · 医学
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates.
1区 · 医学
作者: Nerea Zabaleta ; Wenlong Dai ; Urja Bhatt ; Cécile Hérate ; Pauline Maisonnasse ; Jessica A Chichester ; Julio Sanmiguel ; Reynette Estelien ; Kristofer T Michalson ; Cheikh Diop ; Dawid Maciorowski ; Nathalie Dereuddre-Bosquet ; Mariangela Cavarelli ; Anne-Sophie Gallouët ; Thibaut Naninck ; Nidhal Kahlaoui ; Julien Lemaitre ; Wenbin Qi ; Elissa Hudspeth ; Allison Cucalon ; Cecilia D Dyer ; M Betina Pampena ; James J Knox ; Regina C LaRocque ; Richelle C Charles ; Dan Li ; Maya Kim ; Abigail Sheridan ; Nadia Storm ; Rebecca I Johnson ; Jared Feldman ; Blake M Hauser ; Vanessa Contreras ; Romain Marlin ; Raphaël Ho Tsong Fang ; Catherine Chapon ; Sylvie van der Werf ; Eric Zinn ; Aisling Ryan ; Dione T Kobayashi ; Ruchi Chauhan ; Marion McGlynn ; Edward T Ryan ; Aaron G Schmidt ; Brian Price ; Anna Honko ; Anthony Griffiths ; Sam Yaghmour ; Robert Hodge ; Michael R Betts ; Mason W Freeman ; James M Wilson ; Roger Le Grand ; Luk H Vandenberghe
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity in mouse and non-human primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans and does not elicit cross-reactivity to common AAVs used in gene therapy. Vector genome persistence and expression wanes following injection. The single low-dose requirement, high-yield manufacturability, and 1-month stability for storage at room temperature may make this technology well suited to support effective immunization campaigns for emerging pathogens on a global scale.
2021-01-05·bioRxiv : the preprint server for biology
Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates.
作者: Nerea Zabaleta ; Wenlong Dai ; Urja Bhatt ; Jessica A Chichester ; Reynette Estelien ; Julio Sanmiguel ; Kristofer T Michalson ; Cheikh Diop ; Dawid Maciorowski ; Wenbin Qi ; Elissa Hudspeth ; Allison Cucalon ; Cecilia D Dyer ; M Betina Pampena ; James J Knox ; Regina C LaRocque ; Richelle C Charles ; Dan Li ; Maya Kim ; Abigail Sheridan ; Nadia Storm ; Rebecca I Johnson ; Jared Feldman ; Blake M Hauser ; Aisling Ryan ; Dione T Kobayashi ; Ruchi Chauhan ; Marion McGlynn ; Edward T Ryan ; Aaron G Schmidt ; Brian Price ; Anna Honko ; Anthony Griffiths ; Sam Yaghmour ; Robert Hodge ; Michael R Betts ; Mason W Freeman ; James M Wilson ; Luk H Vandenberghe
The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.
项与 COVID-19 vaccine (Mass General Brigham) 相关的新闻（医药）
Gene therapy encompasses an advanced medical treatment for numerous chronic and genetic disorders in humans. This is achieved by replacing a defective gene cell with a healthy gene cell. Through gene therapy, chronic and genetic disorders that do not have developed cures can be prevented. Developers of gene therapy are quickly expanding their businesses through acquisitions and mergers. New product launch deals are being signed as a strategy to strengthen product trails and augment in-house proficiency.
Onslaught of the COVID-19 pandemic has accelerated the application of gene therapy. Technology for gene and cell therapy is anticipated to be excessively applied for developing vaccines. In January 2019, Mass General Brigham developed vaccine candidates which stimulated convincing immune responses from animal models in treatment of the novel coronavirus. The vaccine candidate named AAVCOVID, was developed through gene-therapy technology and received a grant of USD 2.1 Million for further research. Similarly, researchers from the University of Pennsylvania have started using adeno-associated viral vectors to transmit lab-made antibodies into the body.
基因疗法新型冠状病毒感染COVID-19 vaccine (Mass General Brigham)疫苗抗体细胞疗法并购
100 项与 COVID-19 vaccine (Mass General Brigham) 相关的药物交易